The letter by Tsuda1 raises the question of whether bradykinin contributes to the effects of chronic intracerebroventricular angiotensin (Ang)-(1-7) to enhance baroreflex function in hypertensive (mRen2)27 rats. Our studies exclusively focused on the effects of Ang-(1-7) on NADPH oxidase and mitogen-activated protein kinase signaling pathways in the brain dorsal medulla relative to baroreflex and blood pressure responses. Thus, we cannot provide additional insight regarding the contribution of bradykinin to these responses. It is well established that there are interactions between bradykinin and Ang-(1-7), as well as other components of the RAS that may reflect an interaction through the common metabolism pathway involving angiotensin-converting enzyme, release of bradykinin by Ang-(1-7), or potential receptor interactions.2–5 In an earlier study, however, we demonstrated that the effects of a peptidic angiotensin-converting enzyme inhibitor injected acutely into the nucleus of the solitary tract were mediated primarily by Ang-(1-7) but not by bradykinin.6 Specifically, the selective Ang-(1-7) antagonist d-Ala7-Ang-(1-7) (A779) blocked the improvement in the baroreflex, but the bradykinin antagonist HOE 140 had no effect in that study.
Footnotes
Disclosures
None.
Contributor Information
Manisha Nautiyal, Hypertension and Vascular Research Center, Wake Forest University School of Medicine, Winston-Salem, NC.
Hossam A. Shaltout, Hypertension and Vascular Research Center, Wake Forest University School of Medicine, Winston-Salem, NC
Daniel C. de Lima, Hypertension and Vascular Research Center, Wake Forest University School of Medicine, Winston-Salem, NC
Kenia do Nascimento, Hypertension and Vascular Research Center, Wake Forest University School of Medicine, Winston-Salem, NC.
Mark C. Chappell, Hypertension and Vascular Research Center, Wake Forest University School of Medicine, Winston-Salem, NC Department of General Surgery, Wake Forest University School of Medicine, Winston-Salem, NC.
Debra I. Diz, Hypertension and Vascular Research Center, Wake Forest University School of Medicine, Winston-Salem, NC Department of General Surgery, Wake Forest University School of Medicine, Winston-Salem, NC.
References
- 1.Tsuda K Angiotensin-(1-7) and bradykinin in baroreceptor reflex sensitivity in hypertension. Hypertension. 2013;61:e19. [DOI] [PubMed] [Google Scholar]
- 2.Chappell MC, Pirro NT, Sykes A, Ferrario CM. Metabolism of angiotensin-(1-7) by angiotensin-converting enzyme. Hypertension. 1998;31(1 Pt 2):362–367. [DOI] [PubMed] [Google Scholar]
- 3.Bomtempo CA, Santos GF, Santos RA, Campagnole-Santos MJ. Interaction of bradykinin and angiotensin-(1-7) in the central modulation of the baroreflex control of the heart rate. J Hypertens. 1998;16(12 Pt 1):1797–1804. [DOI] [PubMed] [Google Scholar]
- 4.Bergaya S, Hilgers RH, Meneton P, Dong Y, Bloch-Faure M, Inagami T, Alhenc-Gelas F, Lévy BI, Boulanger CM. Flow-dependent dilation mediated by endogenous kinins requires angiotensin AT2 receptors. Circ Res. 2004;94:1623–1629. [DOI] [PubMed] [Google Scholar]
- 5.Heitsch H, Brovkovych S, Malinski T, Wiemer G. Angiotensin-(1-7)-stimulated nitric oxide and superoxide release from endothelial cells. Hypertension. 2001;37:72–76. [DOI] [PubMed] [Google Scholar]
- 6.Isa K, Arnold AC, Westwood BM, Chappell MC, Diz DI. Angiotensin-converting enzyme inhibition, but not AT(1) receptor blockade, in the solitary tract nucleus improves baroreflex sensitivity in anesthetized transgenic hypertensive (mRen2)27 rats. Hypertens Res. 2011;34: 1257–1262. [DOI] [PMC free article] [PubMed] [Google Scholar]